Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 2/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890515 | 0.87 | GRIN2B (0.32) | NR1H2NR1H3HDAC8MAPK1RXRA | |
| SCHEMBL30890644 | 0.82 | NR1H2 (0.40) | IMPDH2PTPN1NR1H2NR1H3RXRA | |
| SCHEMBL30445475 | 0.81 | IMPDH2 (0.41) | IMPDH2PTPN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL30445328 | 0.81 | IMPDH2 (0.39) | IMPDH2PTPN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL30890521 | 0.80 | LMNA (0.36) | ALDH1A1KMT2A | |
| SCHEMBL30444941 | 0.80 | IMPDH2 (0.38) | IMPDH2PTPN1NR1H2NR1H3HDAC8 | |
| SCHEMBL15658598 | 0.78 | IMPDH2 (0.40) | IMPDH2PTPN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL8250917 | 0.78 | IMPDH2 (0.42) | IMPDH2PTPN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL30992280 | 0.76 | IMPDH2 (0.44) | IMPDH2PTPN1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL30992228 | 0.76 | NFKB1 (0.33) | IMPDH2ALDH1A1HDAC8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | IMPDH2 1033/4885PTPN1 1570/4885NR1H2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.